All In Biotech

Drug Trial Radar · NCT07018050

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

A Multicenter, Open-Label Phase II Study to Evaluate QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Sep 12, 2025

Primary completion

Nov 2027

Study completion Jul 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • QLS32015Drug

    QLS32015 will be administered subcutaneously

  • PomalidomideDrug

    Pomalidomide will be self-administered as a single dose orally

  • DexamethasoneDrug

    Dexamethasone will be administered orally or intravenously

  • QL2109 or DaratumumabDrug

    QL2109 or Daratumumab will be administered subcutaneously.

  • BortezomibDrug

    Bortezomib will be administered subcutaneously

  • LenalidomideDrug

    Lenalidomide will be self-administered as a single dose orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR (Partial Response [PR] or Better)Time frame: Up to 2 years
  2. Overall Minimal Residual Disease (MRD)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.